<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01254045</url>
  </required_header>
  <id_info>
    <org_study_id>SU-11182010-7215</org_study_id>
    <secondary_id>8618</secondary_id>
    <nct_id>NCT01254045</nct_id>
  </id_info>
  <brief_title>Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome</brief_title>
  <official_title>Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the medication oxytocin is an effective and
      tolerable treatment in adolescent males with fragile X syndrome (FraX) for improving socially
      appropriate behaviors and reducing social anxiety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twelve male adolescent (13-24 years) subjects with confirmed genetic diagnosis of FraX (full
      mutation) will participate in this randomized double-blind placebo-controlled study. They
      will receive a dose of either 24 IU oxytocin, 48 IU oxytocin or placebo at each of three
      visits to the lab, with each visit spaced one week apart. The efficacy of each dose will be
      evaluated using behavioral, cognitive and physiological metrics. If individual subject
      results suggest that either of the oxytocin dosage levels (24 IU or 48 IU) is superior to
      placebo in the double-blind phase, a single-blind trial using the optimal dosage of oxytocin
      will then be administered daily for 14 days by parents at home. Subjects will then come into
      the lab for a final assessment on Day 30. Determination of beneficial response to oxytocin
      will be based on a 20% change (improvement) in behavior or test performance (see below). If
      both oxytocin dosage levels provide similar benefits compared to placebo, the lower dose will
      be chosen for the 14 day single-blind trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eye Contact/Gaze During 10 Minute Social Challenge Task</measure>
    <time_frame>baseline, week 2, and week 3</time_frame>
    <description>Number of times that eye gaze occurred (i.e., participant looked at female experimenter in the eyes) during 10 minute social challenge task (first 5 minutes social proximity, second 5 minutes social interaction). The social challenge task occurred 50 minutes after internasal dose (of placebo, placebo + oxytocin, or oxytocin) at baseline, week 2, and week 3 visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Salivary Cortisol</measure>
    <time_frame>baseline, week 2, and week 3</time_frame>
    <description>salivary cortisol level measured immediately before social challenge task and 20 minutes following social challenge task at each time point (i.e., baseline, week 2, and week 3)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Fragile X Syndrome</condition>
  <arm_group>
    <arm_group_label>placebo, oxytocin 24IU, oxytocin 48IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranasal placebo (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxytocin 24IU, placebo, oxytocin 48IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxytocin 48IU, oxytocin 24IU, placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranasal oxytocin (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxytocin 24IU, oxytocin 48IU, placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxytocin 48IU, placebo, oxytocin 24IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranasal oxytocin (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles ; intranasal oxytocin (24 international units) and intranasal placebo (24 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, oxytocin 48IU, oxytocin 24IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranasal placebo (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>intranasal placebo (48 international units)</description>
    <arm_group_label>placebo, oxytocin 24IU, oxytocin 48IU</arm_group_label>
    <arm_group_label>oxytocin 24IU, placebo, oxytocin 48IU</arm_group_label>
    <arm_group_label>oxytocin 48IU, oxytocin 24IU, placebo</arm_group_label>
    <arm_group_label>oxytocin 24IU, oxytocin 48IU, placebo</arm_group_label>
    <arm_group_label>oxytocin 48IU, placebo, oxytocin 24IU</arm_group_label>
    <arm_group_label>placebo, oxytocin 48IU, oxytocin 24IU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin 24IU</intervention_name>
    <description>intranasal oxytocin (24 international units) and intranasal placebo (24 international units)</description>
    <arm_group_label>placebo, oxytocin 24IU, oxytocin 48IU</arm_group_label>
    <arm_group_label>oxytocin 24IU, placebo, oxytocin 48IU</arm_group_label>
    <arm_group_label>oxytocin 48IU, oxytocin 24IU, placebo</arm_group_label>
    <arm_group_label>oxytocin 24IU, oxytocin 48IU, placebo</arm_group_label>
    <arm_group_label>oxytocin 48IU, placebo, oxytocin 24IU</arm_group_label>
    <arm_group_label>placebo, oxytocin 48IU, oxytocin 24IU</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin 48IU</intervention_name>
    <description>intranasal oxytocin (48 international units)</description>
    <arm_group_label>placebo, oxytocin 24IU, oxytocin 48IU</arm_group_label>
    <arm_group_label>oxytocin 24IU, placebo, oxytocin 48IU</arm_group_label>
    <arm_group_label>oxytocin 48IU, oxytocin 24IU, placebo</arm_group_label>
    <arm_group_label>oxytocin 24IU, oxytocin 48IU, placebo</arm_group_label>
    <arm_group_label>oxytocin 48IU, placebo, oxytocin 24IU</arm_group_label>
    <arm_group_label>placebo, oxytocin 48IU, oxytocin 24IU</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed genetic diagnosis of Fragile X (FraX) (full mutation).

          2. Male (who have more serious effects due to the X chromosome nature of the disorder)

          3. Age 13-29 years.

          4. Parent of adolescent must be willing to sign informed consent.

          5. Intelligence Quotient (IQ) &gt; 42.

        Exclusion Criteria:

          1. Cardiac risk factors.

          2. Medication exclusions: opiates or opiate antagonists, corticosteroids, typical or
             atypical antipsychotics.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan L Reiss</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hall SS, Lightbody AA, McCarthy BE, Parker KJ, Reiss AL. Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology. 2012 Apr;37(4):509-18. doi: 10.1016/j.psyneuen.2011.07.020. Epub 2011 Aug 20.</citation>
    <PMID>21862226</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2010</study_first_submitted>
  <study_first_submitted_qc>December 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2010</study_first_posted>
  <results_first_submitted>August 3, 2011</results_first_submitted>
  <results_first_submitted_qc>August 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2014</results_first_posted>
  <last_update_submitted>August 28, 2014</last_update_submitted>
  <last_update_submitted_qc>August 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fragile X Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Ten enrolled. One on antipsychotic mediation at baseline excluded, and one lost to follow-up after baseline. Eight participants included in data analysis. Each participant received a dose of either oxytocin(OT) 24 international units (IU)/intranasal placebo 24IU, OT 48IU, or placebo 48IU at each of 3 weekly visits.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo 48IU, Oxytocin 24IU/Placebo 24IU, Oxytocin 48IU</title>
          <description>intranasal placebo (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and placebo (24 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles</description>
        </group>
        <group group_id="P2">
          <title>Oxytocin 24IU/Placebo 24IU, Placebo 48IU, Oxytocin 48IU</title>
          <description>intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles</description>
        </group>
        <group group_id="P3">
          <title>Oxytocin 48IU, Oxytocin 24IU/Placebo 24IU, Placebo 48IU</title>
          <description>intranasal oxytocin (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles</description>
        </group>
        <group group_id="P4">
          <title>Oxytocin 24IU/Placebo 24IU, Oxytocin 48IU, Placebo 48IU</title>
          <description>intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles</description>
        </group>
        <group group_id="P5">
          <title>Oxytocin 48IU, Placebo 48IU, Oxytocin 24IU/Placebo 24IU</title>
          <description>intranasal oxytocin (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles ; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles</description>
        </group>
        <group group_id="P6">
          <title>Placebo 48IU, Oxytocin 48IU, Oxytocin 24IU/Placebo 24IU</title>
          <description>intranasal placebo (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First/Baseline (1 Day at Week 1 )</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2">One completed all baseline measures including administration of placebo, but then lost to follow-up.</participants>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second/Time 2 (1 Day at Week 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third/Time 3 (1 Day at Week 3)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Ten enrolled. One not randomized because on antipsychotic mediation at baseline. Nine started and one lost to follow-up after baseline. Eight participants were included in data analysis. Each participant received a dose of either 24IU oxytocin, 48IU oxytocin or placebo at each of 3 visits, spaced 1 wk apart, to the lab (i.e., baseline, wk 2, wk 3).</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Includes groups randomized to one of six different sequences of three interventions (placebo, oxytocin 24IU, oxytocin 48IU).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.89" spread="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Eye Contact/Gaze During 10 Minute Social Challenge Task</title>
        <description>Number of times that eye gaze occurred (i.e., participant looked at female experimenter in the eyes) during 10 minute social challenge task (first 5 minutes social proximity, second 5 minutes social interaction). The social challenge task occurred 50 minutes after internasal dose (of placebo, placebo + oxytocin, or oxytocin) at baseline, week 2, and week 3 visits.</description>
        <time_frame>baseline, week 2, and week 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo (48IU)</description>
          </group>
          <group group_id="O2">
            <title>Oxytocin 24IU/Placebo 24IU</title>
            <description>24 international units of intranasal oxytocin and 24 international units of placebo</description>
          </group>
          <group group_id="O3">
            <title>48IU OT</title>
            <description>48 international units of intranasal oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Eye Contact/Gaze During 10 Minute Social Challenge Task</title>
          <description>Number of times that eye gaze occurred (i.e., participant looked at female experimenter in the eyes) during 10 minute social challenge task (first 5 minutes social proximity, second 5 minutes social interaction). The social challenge task occurred 50 minutes after internasal dose (of placebo, placebo + oxytocin, or oxytocin) at baseline, week 2, and week 3 visits.</description>
          <units>eye contact/gaze events per 10 minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" spread="3.5"/>
                    <measurement group_id="O2" value="20.9" spread="3.6"/>
                    <measurement group_id="O3" value="17.0" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Salivary Cortisol</title>
        <description>salivary cortisol level measured immediately before social challenge task and 20 minutes following social challenge task at each time point (i.e., baseline, week 2, and week 3)</description>
        <time_frame>baseline, week 2, and week 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo (48 IU)</description>
          </group>
          <group group_id="O2">
            <title>24IU OT</title>
            <description>24 international units of intranasal oxytocin and 24 IU of placebo</description>
          </group>
          <group group_id="O3">
            <title>48IU OT</title>
            <description>48 international units of intranasal oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Salivary Cortisol</title>
          <description>salivary cortisol level measured immediately before social challenge task and 20 minutes following social challenge task at each time point (i.e., baseline, week 2, and week 3)</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.33" spread=".86"/>
                    <measurement group_id="O2" value="4.67" spread=".56"/>
                    <measurement group_id="O3" value="4.37" spread=".92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intervention: Placebo 48IU</title>
          <description>Two participants received placebo 48IU at baseline. Three participants received placebo 48IU at Time 2. Three participants received placebo 48IU at Time 3. This study is a cross-over design.</description>
        </group>
        <group group_id="E2">
          <title>Intervention: Oxytocin 24IU/Placebo 24IU</title>
          <description>Three participants received Oxytocin 24IU/Placebo 24IU at baseline. Three participants received Oxytocin 24IU/Placebo 24IU at Time 2. Two participants received Oxytocin 24IU/Placebo 24IU at Time 3. This study is a cross-over design.</description>
        </group>
        <group group_id="E3">
          <title>Intervention: Oxytocin 48IU</title>
          <description>Three participants received Oxytocin 48IU at baseline. Two participants received Oxytocin 48IU at Time 2. Three participants received Oxytocin 48IU at Time 3. This study is a cross-over design.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Bell's palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott S. Hall, PhD</name_or_title>
      <organization>Stanford University School of Medicine</organization>
      <phone>650-498-4799</phone>
      <email>hallss@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

